Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012
- PMID: 25498208
- PMCID: PMC5765744
- DOI: 10.1016/j.vaccine.2014.11.046
Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012
Abstract
Background: In March 2009, the U.S. Food and Drug Administration licensed an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC [Ixiaro]) for use in adults. The vaccine was licensed based on clinical trial safety data in 3558 JE-VC recipients. It is essential to monitor post-licensure surveillance data to evaluate the safety of JE-VC because rare adverse events may not be detected until the vaccine is administered to a larger population.
Methods: We reviewed adverse events reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) for adults (≥17 years) who received JE-VC from May 2009 through April 2012. Adverse event reporting rates were calculated using 275,848 JE-VC doses distributed.
Results: Over the 3 year period, 42 adverse events following vaccination with JE-VC were reported to VAERS for an overall reporting rate of 15.2 adverse events per 100,000 doses distributed. Of the 42 total reports, 5 (12%) were classified as serious for a reporting rate of 1.8 per 100,000 doses distributed; there were no deaths. Hypersensitivity reactions (N=12) were the most commonly reported type of adverse event, with a rate of 4.4 per 100,000 doses distributed; no cases of anaphylaxis were reported. Three adverse events of the central nervous system were reported (one case of encephalitis and two seizures) for a rate of 1.1 per 100,000; all occurred after receipt of JE-VC with other vaccines.
Conclusions: These post-marketing surveillance data suggest a good safety profile for JE-VC consistent with findings from pre-licensure clinical trials. Post-licensure safety data should continue to be monitored for any evidence of rare serious or neurologic adverse events.
Keywords: Japanese encephalitis vaccines; Public health surveillance; United States; Vaccines.
Published by Elsevier Ltd.
Conflict of interest statement
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. No writing assistance was utilized in the production of this manuscript.
Similar articles
-
Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012-2016.Vaccine. 2018 Jul 5;36(29):4369-4374. doi: 10.1016/j.vaccine.2018.04.038. Epub 2018 Jun 8. Vaccine. 2018. PMID: 29891351 Free PMC article.
-
Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.Vaccine. 2018 Mar 7;36(11):1398-1404. doi: 10.1016/j.vaccine.2018.01.075. Vaccine. 2018. PMID: 29429815
-
The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis.Expert Rev Vaccines. 2015;14(9):1167-79. doi: 10.1586/14760584.2015.1061939. Epub 2015 Jul 10. Expert Rev Vaccines. 2015. PMID: 26162529 Review.
-
Adverse event reports following Japanese encephalitis vaccination in the United States, 1999-2009.Vaccine. 2010 Dec 10;29(1):58-64. doi: 10.1016/j.vaccine.2010.10.016. Epub 2010 Nov 4. Vaccine. 2010. PMID: 20970488
-
Allergic reactions to Japanese encephalitis vaccine.Immunol Allergy Clin North Am. 2003 Nov;23(4):665-97. doi: 10.1016/s0889-8561(03)00102-4. Immunol Allergy Clin North Am. 2003. PMID: 14753386 Review.
Cited by
-
Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011-August 2019.Vaccine. 2023 Feb 24;41(9):1537-1540. doi: 10.1016/j.vaccine.2023.01.061. Epub 2023 Jan 30. Vaccine. 2023. PMID: 36725428 Free PMC article.
-
Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices.MMWR Recomm Rep. 2019 Jul 19;68(2):1-33. doi: 10.15585/mmwr.rr6802a1. MMWR Recomm Rep. 2019. PMID: 31518342 Free PMC article.
-
Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012-2016.Vaccine. 2018 Jul 5;36(29):4369-4374. doi: 10.1016/j.vaccine.2018.04.038. Epub 2018 Jun 8. Vaccine. 2018. PMID: 29891351 Free PMC article.
-
International Consensus (ICON): allergic reactions to vaccines.World Allergy Organ J. 2016 Sep 16;9(1):32. doi: 10.1186/s40413-016-0120-5. eCollection 2016. World Allergy Organ J. 2016. PMID: 27679682 Free PMC article.
References
-
- Centers for Disease Control and Prevention. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2010;59(RR-1):1–27. - PubMed
-
- United States Food and Drug Administration. [accessed 04.03.14];Ixiaro – summary basis for regulatory action. 2009 Available at: http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm1....
-
- Centers for Disease Control and Prevention. Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011. MMWR. 2011;60(20):661–3. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous